High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Investing.com -- Wells Fargo has downgraded Boston Scientific to “Equal Weight” from “Overweight,” citing growing uncertainty around the medical device maker’s two key growth drivers — its electrophysiology (EP) business and the Watchman heart implant franchise.
Boston Scientific (BSX) previously commanded a premium valuation based on its transition toward a high-margin cardiovascular powerhouse, driven by its FARAPULSE Pulsed Field Ablation (PFA) system and WATCHMAN cardiac implant. In Q1 2026, the cardiovascular segment posted a strong 13.5% reported growth. However, intense competition from Medtronic (MDT) and Johnson & Johnson (JNJ) has challenged this hyper-growth thesis. Johnson & Johnson's Varipulse system integrates directly into the dominant CA
Investors have recently become less willing to tolerate compressed margins tied to rising costs and slowing demand.
Boston Scientific Corporation (NYSE:BSX) is one of the best medical technology stocks to buy right now. On May 19, TD Cowen reiterated its Buy rating and $80 price target on Boston Scientific Corporation (NYSE:BSX). TD Cowen constructed its thesis around Boston Scientific’s Fracture IDE study. The study tested the company’s SEISMIQ 4CE Coronary Intravascular Lithotripsy […]
Investors weigh softer WATCHMAN and urology demand against a still-active device pipeline and capital deployment moves, today, May 27, 2026.
US equity indexes were higher on Wednesday after a decline in crude oil prices and government bond y
The medical device maker flags a drop in stand-alone procedures for its Watchman heart implant, hitting its near-term growth forecast.
The medical device giant just opened its wallet for a stake in a privately held company with a groundbreaking product.
Zscaler (ZS) shares plunged 31% intraday after the company issued a fiscal Q4 revenue outlook that m
Boston Scientific's CEO stated that the company will update its three-year plan, including targets for FY27 and FY28, after the third-quarter earnings call.
NPCE bets on AI ECoG Assistant and cloud upgrades as it refocuses on RNS, while IGE label review and coverage timing loom.
Investing.com -- Boston Scientific Corp (NYSE:BSX) fell over 6% Wednesday after management lowered its full-year guidance during a presentation at Bernstein.
This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease.
WATCHMAN's 19% growth and trial wins bolster Boston Scientific's push to expand its addressable market from 5M to 20M patients worldwide.
Boston Scientific Corporation (NYSE:BSX) is one of the best medical stocks to invest in according to billionaires. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $68 from $105 on May 18, reaffirming a Buy rating on the shares. The firm told investors that after having hosted 34 medtech companies last week in […]
Boston Scientific (NYSE:BSX) has initiated two voluntary recalls of its LUX-Dx II arrhythmia detector and alarm devices. The recalls follow FDA enforcement reports citing failures in data collection and monitoring of critical cardiac events for certain patients. Issues include discrepancies in device programming interfaces that affect reliability of arrhythmia monitoring and treatment decisions. The recalls are ongoing and affect patients and clinicians in multiple regions, including the US...
Biotech firm Nektar Therapeutics advances a pipeline of immunology and oncology candidates through research-driven collaborations.
GeneDx Holdings delivers AI-powered clinical and genomic data analysis for healthcare providers seeking precision medicine solutions.
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ISRG's SP platform sees Q1 2026 procedures jump 68%, with new approvals and tools raising a key question: TAM expansion or procedure shift?
Globus Medical, Inc. (NYSE:GMED) was among the stocks Jim Cramer looked at as he explained the need for a tame bond market for the stock market to go higher. A caller asked for Cramer’s thoughts on the company, and he remarked: Okay, this group in particular, the medical device group, is hated in this market. […]
Boston Scientific (NYSE:BSX) reported positive pivotal trial results for its SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter. The FRACTURE trial met all primary safety and effectiveness endpoints in patients with severely calcified coronary artery disease. The company plans to use these data to support a regulatory submission for SEISMIQ 4CE. Boston Scientific is a major player in interventional cardiology, with products focused on treating complex coronary and structural heart...
TCW Funds, an investment management firm, published its first-quarter 2026 investor letter for the ‘TCW Concentrated Large Cap Growth Fund.’ A copy of the letter is available to download here. The first quarter was marked by volatility in equity markets, driven by geopolitical tensions, concerns about the private credit sector, a government shutdown, and ongoing […]
ABT's EPD unit posts 9% Q1 sales growth as biosimilars and emerging market demand support its long-term expansion plans.
With a 5-year average revenue growth rate of 13.52%, Boston Scientific Corporation (NASDAQ:BSX) is included among the 11 Best Long Term US Stocks to Buy Right Now. On May 19, Baird lowered its price recommendation on Boston Scientific Corporation (NASDAQ:BSX) to $75 from $78. It reiterated an Outperform rating on the shares. The firm updated its model […]
Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index and the State Street H
Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.1% and the State S
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.